BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33475012)

  • 1. Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.
    Hu-Lieskovan S; Malouf GG; Jacobs I; Chou J; Liu L; Johnson ML
    Future Oncol; 2021 Apr; 17(11):1401-1439. PubMed ID: 33475012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
    Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
    Front Immunol; 2020; 11():1956. PubMed ID: 32983126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance.
    Weng CY; Kao CX; Chang TS; Huang YH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33514004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.
    Kobayashi Y; Lim SO; Yamaguchi H
    Semin Cancer Biol; 2020 Oct; 65():51-64. PubMed ID: 31874279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions.
    Zhang C; Zhang C; Wang H
    Cancer Lett; 2023 May; 562():216182. PubMed ID: 37076040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to immune checkpoint inhibitors and the tumor microenvironment.
    Kawashima S; Togashi Y
    Exp Dermatol; 2023 Mar; 32(3):240-249. PubMed ID: 36437644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
    Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
    AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
    Oura K; Morishita A; Tani J; Masaki T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding genetic determinants of resistance to immune checkpoint blockers.
    Aspeslagh S; Chabanon RM; Champiat S; Postel-Vinay S
    Semin Cancer Biol; 2020 Oct; 65():123-139. PubMed ID: 31881338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
    Rivera Vargas T; Apetoh L
    Front Immunol; 2019; 10():1181. PubMed ID: 31191545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treg-mediated acquired resistance to immune checkpoint inhibitors.
    Saleh R; Elkord E
    Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
    Hou A; Hou K; Huang Q; Lei Y; Chen W
    Front Immunol; 2020; 11():783. PubMed ID: 32508809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
    Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
    Front Immunol; 2021; 12():651086. PubMed ID: 34248939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.
    Lee WS; Yang H; Chon HJ; Kim C
    Exp Mol Med; 2020 Sep; 52(9):1475-1485. PubMed ID: 32913278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
    Yao L; Jia G; Lu L; Bao Y; Ma W
    Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
    Pender A; Titmuss E; Pleasance ED; Fan KY; Pearson H; Brown SD; Grisdale CJ; Topham JT; Shen Y; Bonakdar M; Taylor GA; Williamson LM; Mungall KL; Chuah E; Mungall AJ; Moore RA; Lavoie JM; Yip S; Lim H; Renouf DJ; Sun S; Holt RA; Jones SJM; Marra MA; Laskin J
    Clin Cancer Res; 2021 Jan; 27(1):202-212. PubMed ID: 33020056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination.
    De Guillebon E; Dardenne A; Saldmann A; Séguier S; Tran T; Paolini L; Lebbe C; Tartour E
    Int J Cancer; 2020 Sep; 147(6):1509-1518. PubMed ID: 31997345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
    Wang Z; Wang Y; Gao P; Ding J
    Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.